WINNIPEG, Sept. 26, 2011 /CNW/ - IMRIS Inc. (NASDAQ: IMRS; TSX: IM)
("IMRIS" or the "Company") today announced that the first published
results on the early clinical experiences at hospitals using the IMRIS
system, highlight a number of positive findings for procedures and
patient outcomes resulting from utilization of the intraoperative MRI
capabilities available in IMRIS suites.
The studies which were conducted at hospitals in three different
countries each concluded that the IMRIS system can be safely integrated
into neurosurgical workflows and enable intraoperative modification of
surgical strategy in a range of neurosurgical procedures.
The studies included 180 patients treated from April 2008 to July 2009
at the Washington University School of Medicine in St. Louis, Missouri,
USA (Chicoine MR., et al); 45 patients treated between July 2008 and July 2009 at PLA 301
Hospital in Beijing, China, (Xiaolei Chen, et al); and 120 patients who underwent procedures between January 2009 and
November 2009 at University of Calgary Foothills Hospital in Calgary,
Alberta, Canada, (Michael J. Lang, et al).
In 41% of all cases in the Washington University School of Medicine
study and in 48.9% of all cases included in the study at PLA 301
Hospital, the surgeon modified the surgical procedure based upon the
intraoperative MR imaging information provided by the IMRIS suite.
Gross/near total tumor resection was achieved in 93% of patients with
gliomas in the Washington University School of Medicine study, compared
with 65% for procedures that did not utilize the intraoperative MR
imaging capabilities in the same timeframe.
Gross/near total tumor resection was achieved in 76.9% of the pituitary
adenoma procedures in the PLA 301 Hospital preliminary clinical
experience which compared with 38.5% of the procedures having achieved
gross/near total tumor resection prior to the intraoperative MR
From clinical experience with 120 patients, the University of Calgary
Foothills Hospital study found that intraoperative imaging resulted in
modification to surgery in a substantial number of patients and
concluded that intraoperative imaging at 3.0T is safe, reliable and
capable of directing image guided surgery with exceptional image
Links to Abstracts for the studies referenced in this news release are
available at the U.S. National Library of Medicine National Institutes
of Health database website: www.pubmed.gov.
Globally, more than 6,000 procedures have now been completed in IMRIS
suites which are designed to provide timely imaging information to
assist clinicians in making better decisions for improved patient
outcomes. IMRIS suites allow a high field MR scanner to move into an
operating room on demand before, during and after procedures without
moving the patient.
The patient is not required to be transported for scanning, so the
optimum patient positioning is always maintained. Clinical workflow
and access to the patient is not impacted and the MR scanner is removed
completely from the operating room when imaging is complete. This
ensures a high degree of safety for both the patient and the surgical
environment. As well, when not in use for intraoperative imaging, the
MR scanner is available for diagnostic imaging. To date, more than 100
imaging enabled rooms have been selected by leading medical
institutions around the world.
IMRIS (NASDAQ: IMRS; TSX: IM) is a global leader in providing image
guided therapy solutions. These solutions feature fully integrated
surgical and interventional suites that incorporate magnetic resonance,
fluoroscopy and computed tomography to deliver on demand imaging during
procedures. The Company's systems serve the neurosurgical,
cardiovascular and neurovascular markets and have been selected by
leading medical institutions around the world.
IMRIS Surgical Suite: http://www.imris.com/Press_Releases/PR_images/PR-demoSuite-2011-09.jpg
Image with caption: "IMRIS Surgical Suite. (CNW Group/IMRIS Inc.)". Image available at: http://photos.newswire.ca/images/download/20110926_C6461_PHOTO_EN_3789.jpg
SOURCE IMRIS Inc.
For further information:
Director Investor Relations & Corporate Communications